Table 4.

Comparison of each item’s mean change between baseline and 6-month visits, between group A and group B

Parameters	Group A	Group B	P-value
	n=47 (mean ± SD)	n=20 (mean ± SD)
SF-1	21.5±31.8	−14.5±37.2	<0.001
SF-2	35.5±41.5	−13.7±55.8	0.001
SF-3	15.3±24.6	−14.2±30.4	0.001
SF-4	20.7±21.5	−13.6±29.4	<0.001
SF-5	18.8±28.9	−6.2±38.5	0.010
SF-6	24.1±26.6	−9.2±30.8	<0.001
SF-7	35.5±42.8	−16.6±47.7	<0.001
SF-8	21.6±24.8	−14.0±28.6	<0.001
HAD-A	−6.4±6.6	−0.35±6.4	0.001
HAD-D	−5.0±5.5	−1.4±4.7	0.017
ASEX 1	−1.4±1.6	−0.15±1.8	0.021
ASEX 2	−1.3±1.5	0.27±1.79	0.011
ASEX 3	−1.1±1.5	0.00±1.4	0.027
ASEX 4	−1.2±1.5	−0.083±1.8	0.021
ASEX 5	−1.3±1.5	0.75±1.9	0.002
ASEX T	−6.4±5.8	2.5±6.2	<0.001
MMS	−1.6±3.4	−1.7±4.4	0.926
CDAI	−62.9±99.5	−39.3±139.5	0.570
CRP	1.9±13.5	0.04±3.1	0.656
WBC	−0.11±1.2	0.32±2.3	0.548
Hb	0.4±1.2	0.23±0.57	0.928
Htc	0.4±3.7	0.31±1.81	0.723
MCV	−0.8±4.5	−1.37±2.25	0.459
Plt	−10.39±40.93	24.44±46.8	0.016

Notes: SEX 1, drive; ASEX 2, arousal; ASEX 3, penile erection/vaginal lubrication; ASEX 4, ability to reach orgasm; ASEX 5, satisfaction from orgasm; Sf1, SF-36: physical functioning; Sf2, SF-36: role physical; Sf3, SF-36: bodily pain; Sf4, SF-36: general health; Sf5, SF-36: vitality; Sf6, SF-36: social functioning; Sf7, SF-36: role emotional; Sf8, SF-36: mental health. Group A: patients maintained psychiatric drug therapy during 6 months; Group B: patients could not maintain psychiatric drug therapy of 6 months. All boldface values are statistically significant values.

Abbreviations: A ASEX T, ASEX total; CDAI, Crohn’s disease activity index; CRP, C reactive protein; HAD-A, Hospital Anxiety and Depression Scale Anxiety score; HAD-D, Hospital Anxiety and Depression Scale Depression score; Hb, hemoglobin; Htc, hematocrit; MMS, modified Mayo score; MCV, mean corpuscular volume; Plt, platelet; WBC, white blood cell.